Finance News World

DelveInsight, “Eczema Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Eczema Pipeline Report

• DelveInsight’s Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.

• The leading Eczema Companies working in the market include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

• Promising Eczema Therapies in the various stages of development include Mucopolysaccharide Polysulfate Cream, ZL-3101, alitretinoin, LAS41003, Clobetasone Butyrate 0.05% Cream, and others.

• May 2024:- Arcutis Biotherapeutics Inc.- A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects With Atopic Dermatitis. This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).

• May 2024:- Incyte Corporation- A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis. This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.

• May 2024:- Apogee Therapeutics Inc- A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients with Moderate-to-severe Atopic Dermatitis. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

Request a sample and discover the recent advances in Eczema @ Eczema Pipeline Outlook Report

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the “”itch that rashes”” due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups.

Eczema Emerging Drugs Profile

• Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases.

• BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

• LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

Learn more about Eczema in clinical trials @ Eczema Drugs

Eczema Therapeutics Assessment

There are approx. 100+ Eczema companies which are developing the Eczema therapies. The Eczema companies which have their Eczema drug candidates in the most advanced stage, i.e. phase II include, LEO Pharma.

DelveInsight’s Eczema Pipeline Report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Discover more about Eczema in development @ Eczema Clinical Trials

Eczema Companies

Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

To know more about Eczema, visit @ Eczema Segmentation

Scope of the Eczema Pipeline Report

• Coverage- Global

• Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. 

• Eczema Therapies-Mucopolysaccharide Polysulfate Cream, ZL-3101, alitretinoin, LAS41003, Clobetasone Butyrate 0.05% Cream, and others.

For further information on the Eczema Pipeline Therapeutics, reach out @ Eczema Products Development

Table of Content

1. Introduction

2. Executive Summary

3. Eczema: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Eczema– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Drug name : Company name

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. Amlitelimab: Kymab

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. Drug name : Company name

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name : Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Eczema Key Companies

21. Eczema Key Products

22. Eczema- Unmet Needs

23. Eczema- Market Drivers and Barriers

24. Eczema- Future Perspectives and Conclusion

25. Eczema Analyst Views

26. Eczema Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/